Single agent and combination studies of pralatrexate and molecular correlates of sensitivity

British Journal of Cancer

Volumn 104, Issue 2, 2011, Pages 272-280

  Serova, M ^a   Bieche, I ^a   Sablin, M P ^a   Pronk, G J ^b   Vidaud, M ^a   Cvitkovic, E ^a   Faivre, S ^a   Raymond, E ^a  

^a BEAUJON HOSPITAL   (France)

^b Allos Therapeutics Inc   (United States)

Author keywords

antifolates; antimetabolites; combination chemotherapy; drug resistance; folate transporters; methotrexate

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CISPLATIN; DOXIFLURIDINE; ERLOTINIB; FLUOROURACIL; FOLYLPOLYGLUTAMATE SYNTHASE; GEMCITABINE; LAPATINIB; METHOTREXATE; OXALIPLATIN; PACLITAXEL; PEMETREXED; PRALATREXATE; REDUCED FOLATE CARRIER;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; FOLATE METABOLISM; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY ANALYSIS;

AMINOPTERIN; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; FOLIC ACID ANTAGONISTS; HUMANS; METHOTREXATE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 78751474637     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6606063     Document Type: Article

References (25)

1. Appling DR (1991) Compartmentation of folate-mediated one-carbon metabolism in eukaryotes. FASEB J 5: 2645-2651
2. Assaraf YG (2007) Molecular basis of antifolate resistance. Cancer Metastasis Rev 26: 153-181
3. Azzoli CG, Krug LM, Gomez J, Miller VA, Kris MG, Ginsberg MS, Henry R, Jones J, Tyson L, Dunne M, Pizzo B, Farmer A, Venkatraman E, Steffen R, Sirotnak FM (2007) A phase 1 study of pralatrexate in combination with paclitaxel or docetaxel in patients with advanced solid tumors. Clin Cancer Res 13: 2692-2698 (Pubitemid 46788037)
4. Bièche I, Parfait B, Laurendeau I, Girault I, Vidaud M, Lidereau R (2001) Quantification of estrogen receptor alpha and beta expression in sporadic breast cancer. Oncogene 20: 8109-8115
5. Chabner BA, Allegra CJ, Curt GA, Clendeninn NJ, Baram J, Koizumi S, Drake JC, Jolivet J (1985) Polyglutamation of methotrexate. Is methotrexate a prodrug? J Clin Invest 76: 907-912
6. Chen G, Wright JE, Rosowsky A (1995) Dihydrofolate reductase binding and cellular uptake of nonpolyglutamatable antifolates: correlates of cytotoxicity toward methotrexate-sensitive and -resistant human head and neck squamous carcinoma cells. Mol Pharmacol 48: 758-765
7. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55
8. Cocconi G, Cunningham D, Van Cutsem E, Francois E, Gustavsson B, Van Hazel G, Kerr D, Possinger K, Hietschold SM (1998) Open, randomized, multicenter trial of raltitrexed vs fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Study Group. J Clin Oncol 16: 2943-2952
9. DeGraw JI, Colwell WT, Piper JR, Sirotnak FM (1993) Synthesis and antitumor activity of 10-propargyl-10-deazaaminopterin. J Med Chem 36: 2228-2231
10. Farber S, Diamond LK, Mercer RD, Sylvester RF, Wolff JA (1948) Temporary remission in acute leukaemia in children produced by folio acid antagonist 4-aminopteroylglutamic acid (aminopterin). New England J Med 238: 787-793
11. Fotoohi AK, Assaraf YG, Moshfegh A, Hashemi J, Jansen G, Peters GJ, Larsson C, Albertioni F (2009) Gene expression profiling of leukemia T-cells resistant to methotrexate and 7-hydroxymethotrexate reveals alterations that preserve intracellular levels of folate and nucleotide biosynthesis. Biochem Pharmacol 77: 1410-1417
12. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar M, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn Jr PA (2004) Randomized phase III trial of pemetrexed vs docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 22: 1589-1597
13. Hansen MB, Nielsen SE, Berg K (1989) Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 119: 203-210
14. Ifergan I, Meller I, Issakov J, Assaraf YG (2003) Reduced folate carrier protein expression in osteosarcoma: implications for the prediction of tumor chemosensitivity. Cancer 98: 1958-1966
15. Izbicka E, Diaz A, Streeper R, Wick M, Campos D, Steffen R, Saunders M (2009) Distinct mechanistic activity profile of pralatrexate in comparison to other antifolates in in vitro and in vivo models of human cancers. Cancer Chemother Pharmacol 64: 993-999
16. Jansen G, Pieters R (1998) The role of impaired transport in (pre)clinical resistance to methotrexate: insights on new antifolates. Drug Resist Updat 1: 211-218
17. Marneros AG, Grossman ME, Silvers DN, Husain S, Nuovo GJ, MacGregor-Cortelli B, Neylon E, Patterson M, O'Connor OA, Zain JM (2009) Pralatrexate-induced tumor cell apoptosis in the epidermis of a patient with HTLV-1 adult T-cell lymphoma/leukemia causing skin erosions. Blood 113: 6338-6341
18. Mauritz R, Peters GJ, Priest DG, Assaraf YG, Drori S, Kathmann I, Noordhuis P, Bunni MA, Rosowsky A, Schornagel JH, Pinedo HM, Jansen G (2002) Multiple mechanisms of resistance to metho-trexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis. Biochem Pharmacol 63: 105-115
19. O'Connor OA, Hamlin PA, Portlock C, Moskowitz CH, Noy A, Straus DJ, Macgregor-Cortelli B, Neylon E, Sarasohn D, Dumetrescu O, Mould DR, Fleischer M, Zelenetz AD, Sirotnak F, Horwitz S (2007) Pralatrexate, a novel class of antifolates with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma. Br J Haematol 139: 425-428
20. Odin E, Wettergren Y, Nilsson S, Willén R, Carlsson G, Spears CP, Larsson L, Gustavsson B (2003) Altered gene expression of folate enzymes in adjacent mucosa is associated with outcome of colorectal cancer patients. Clin Cancer Res 9: 6012-6019
21. Rothem L, Stark M, Assaraf YG (2004) Impaired CREB-1 phosphorylation in antifolate-resistant cell lines with down-regulation of the reduced folate carrier gene. Mol Pharmacol 66: 1536-1543
22. Sirotnak FM, DeGraw JI, Colwell WT, Piper JR (1998) A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice. Cancer Chemother Pharmacol 42: 313-318
23. Toner LE, Vrhovac R, Smith EA, Gardner J, Heaney M, Gonen M, Teruya-Feldstein J, Sirotnak F, O'Connor OA (2006) The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin's lymphoma. Clin Cancer Res 12: 924-932
24. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P (2003) Phase III study of pemetrexed in combination with cisplatin vs cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21: 2630-2636
25. Wang ES, O'Connor O, She Y, Zelenetz AD, Sirotnak FM, Moore MA (2003) Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression. Leuk Lymphoma 44: 1027-1035